EMA Authorised: Mulpleo (previously Lusutrombopag Shionogi) (Lusutrombopag) — Shionogi B.V.

View source ↗

Summary

Mulpleo (lusutrombopag) has been authorised in the EU for thrombocytopenia with Shionogi B.V. as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• Mulpleo (lusutrombopag)

Snippet

Status: Authorised. Therapeutic area: Thrombocytopenia. MAH: Shionogi B.V.. Decision date: 05/01/2024